MDS Nordion Offers Advanced Cancer Therapy Systems in Europe
Ottawa, Canada (ots/PRNewswire)
The MDS Nordion Equinox, a state-of-the-art cancer therapy system, and Avanza, a patient positioning treatment table, have received CE Mark approval and are now commercially available in Europe.
The Equinox is a unique external beam therapy system providing cancer care professionals with modern functionality to maximize productivity and increase flexibility ensuring patients receive advanced, timely care. The Avanza patient positioning treatment table offers health care providers with stability and accuracy and supports all modern treatment techniques, including specialized treatments that require precision and reproducibility.
"The need to improve timely access to cancer treatment is increasingly a concern in Europe and across the global cancer-care community," says Jim Warrington, Head of Radiotherapy Physics, at the Royal Marsden, Sutton, England. "Cancer care professionals need efficient and effective cancer tools like MDS Nordion's Equinox and Avanza to manage workload and provide patients with quality care when they need it."
According to the World Health Organization, across the globe, rates of cancer are on the rise. In 2004, Europe diagnosed nearly 2.9 million new cancer cases and had more than 1.7 million cancer deaths demonstrating the increased need for sophisticated, accessible and efficient treatment options.
"Today's oncology clinics need practical solutions to meet clinical challenges as the demand for treatment services increases world-wide," said Steve West, President of MDS Nordion. "We are proud to be offering the European medical community and its patients our advanced cancer therapy system that delivers predictable outcomes with timely and effective treatment."
The Equinox represents MDS Nordion's continued commitment to deliver reliable, efficient and effective patient care solutions. Recognized as a leader in quality and regulatory excellence, some 1,200 MDS Nordion cancer therapy systems deliver 45,000 cancer treatments in over 80 countries every day.
About MDS Nordion
MDS Nordion (www.mds.nordion.com) is a world leader in radioisotopes, radiation and related technologies. MDS Nordion is part of MDS Inc. (TSX:MDS; NYSE:MDZ). MDS Inc. has more than 8,800 highly skilled people in 28 countries. We provide a diverse range of superior products and services to increase our customers' speed, precision and productivity in the drug development and disease diagnosis processes. We are a global, values-driven health and life sciences company, recognized for our reliability and collaborative relationships as we help create better outcomes in the treatment of disease. Find out more at www.mdsinc.com or by calling +1-888-MDS-7222, 24 hours a day.
Contact:
Shelley Maclean, External Communications Specialist, MDS Nordion,
Tel: +1-613-592-3400 ext. 2414, E-mail: shelley.maclean@mdsinc.com